Corpus ID: 29905234

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

@article{Russo2004ClinicalED,
  title={Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?},
  author={Ethan B. Russo},
  journal={Neuro endocrinology letters},
  year={2004},
  volume={25 1-2},
  pages={
          31-9
        }
}

• Ethan B. Russo
• Published 2004
• Medicine
• Neuro endocrinology letters

OBJECTIVES This study examines the concept of clinical endocannabinoid deficiency (CECD), and the prospect that it could underlie the pathophysiology of migraine, fibromyalgia, irritable bowel syndrome, and other functional conditions alleviated by clinical cannabis. METHODS Available literature was reviewed, and literature searches pursued via the National Library of Medicine database and other resources. RESULTS Migraine has numerous relationships to endocannabinoid function. Anandamide… Expand

View on PubMed

alchimiaweb.com

Save to Library

Create Alert

Cite

Launch Research Feed